US20040192913A1 - Process for the racemization of chiral quinazolinones - Google Patents
Process for the racemization of chiral quinazolinones Download PDFInfo
- Publication number
- US20040192913A1 US20040192913A1 US10/773,602 US77360204A US2004192913A1 US 20040192913 A1 US20040192913 A1 US 20040192913A1 US 77360204 A US77360204 A US 77360204A US 2004192913 A1 US2004192913 A1 US 2004192913A1
- Authority
- US
- United States
- Prior art keywords
- substituted
- alkyl
- aryl
- heteroaryl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *C([2*])(C1=NC2=C(C(=O)N1[1*])C([5*])=C([6*])C([7*])=C2[8*])N([4*])C([3*])=O.*C([2*])(C1=NC2=C(C(=O)N1[1*])C([5*])=C([6*])C([7*])=C2[8*])N([4*])[H].*CN([4*])C(*)([2*])C1=NC2=C(C(=O)N1[1*])C([5*])=C([6*])C([7*])=C2[8*].*ON([4*])C(*)([2*])C1=NC2=C(C(=O)N1[1*])C([5*])=C([6*])C([7*])=C2[8*].O=S Chemical compound *C([2*])(C1=NC2=C(C(=O)N1[1*])C([5*])=C([6*])C([7*])=C2[8*])N([4*])C([3*])=O.*C([2*])(C1=NC2=C(C(=O)N1[1*])C([5*])=C([6*])C([7*])=C2[8*])N([4*])[H].*CN([4*])C(*)([2*])C1=NC2=C(C(=O)N1[1*])C([5*])=C([6*])C([7*])=C2[8*].*ON([4*])C(*)([2*])C1=NC2=C(C(=O)N1[1*])C([5*])=C([6*])C([7*])=C2[8*].O=S 0.000 description 13
- ZHXJPULBSFVCKA-UHFFFAOYSA-N CC(C1=NC2=CC=CC=C2C(=O)N1CC1=CC=CC=C1)N(CCN)C(=O)C1=CC=C(Br)C=C1.CCC(C1=NC2=CC(Cl)=CC=C2C(=O)N1CC1=CC=CC=C1)N(CCN)C(=O)C1=CC=C(Br)C=C1 Chemical compound CC(C1=NC2=CC=CC=C2C(=O)N1CC1=CC=CC=C1)N(CCN)C(=O)C1=CC=C(Br)C=C1.CCC(C1=NC2=CC(Cl)=CC=C2C(=O)N1CC1=CC=CC=C1)N(CCN)C(=O)C1=CC=C(Br)C=C1 ZHXJPULBSFVCKA-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
Definitions
- This invention relates to a process for racemizing one of the enantiomers, or an enantiomerically enriched mixture, of an optically active compound. This invention more specifically relates to racemization of quinazolinone derivatives.
- Quinazolinones are among a growing number of therapeutic agents used to treat cell proliferative disorders, including cancer.
- PCT WO 01/30768 which is incorporated herein by reference in its entirety, describes a pharmaceutical composition containing quinazolinone derivatives which are inhibitors of the mitotic kinesin KSP and are useful in the treatment of cellular proliferative diseases, for example cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders and inflammation.
- Certain of the compounds described therein have the following formula:
- R 1 is chosen from hydrogen, alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, substituted alkyl, substituted aryl, substituted aralkyl, substituted heteroaryl, and substituted heteroaralkyl;
- R 2 and R 2 ′ are independently chosen from hydrogen, alkyl, oxaalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, substituted alkyl, substituted aryl, substituted aralkyl, substituted heteroaryl, and substituted heteroaralkyl; or R 2 and R 2 ′ taken together form a 3- to 7-membered ring;
- R 3 is chosen from hydrogen, alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, substituted alkyl, substituted aryl, substituted aralkyl, substituted heteroaryl, substituted heteroaralkyl, oxaalkyl, oxaaralkyl, substituted oxaaralkyl, R 15 O— and R 15 —NH—;
- R 3a is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl and R 15 —NH—;
- R 3b is chosen from alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl;
- R 4 is chosen from hydrogen, alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, substituted alkyl, substituted aryl, substituted aralkyl, substituted heteroaryl, substituted heteroaralkyl, and R 16 -alkylene-;
- R 5 , R 6 , R 7 and R 8 are independently chosen from hydrogen, alkyl, alkoxy, halogen, fluoroalkyl, nitro, dialkylamino, alkylsulfonyl, alkylsulfonamido, sulfonamidoalkyl, sulfonamidoaryl, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, aryl and heretoaryl;
- R 15 is chosen from alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, substituted alkyl, substituted aryl, substituted aralkyl, substituted heteroaryl, and substituted heteroaralkyl;
- R 16 is chosen from alkoxy, amino, alkylamino, dialkylamino, N-heterocyclyl and substituted N-heterocyclyl.
- quinazolinone derivatives have an asymmetric carbon atom (i.e., the stereogenic center to which R 2 and R 2 are attached) that may exist as a racemic mixture of these compounds, i.e., a mixture of both the (+) and ( ⁇ ) or dextro and levo rotary forms. These compounds can be produced as racemates and administered in this form. However, it is known that the physiological utility of racemic mixtures often is focused on one enantiomer, the other having either little or no effect or even diminishing the effect of the active enantiomer.
- FIGS. 1 and 2 A generic synthetic scheme for the preparation of quinazolinone compounds of Formula I(a)-(d) above is described in PCT WO 01/30768 and is shown in FIGS. 1 and 2.
- An asymmetric synthesis of the quinazolinone compounds of Formula I using optically active reagents is shown in FIG. 3.
- Disposal of the undesired enantiomer of an intermediate is not environmentally or economically desirable.
- an efficient method of converting the inactive or undesirable enantiomer into the other usable, desirable enantiomer is a commercially important objective. This invention makes it possible to achieve this objective.
- the present invention provides a method for racemizing one of the enantiomers, or an enantiomerically enriched mixture, of an optically active compound of the formula:
- R 1 is chosen from hydrogen, alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, substituted alkyl, substituted aryl, substituted aralkyl, substituted heteroaryl, and substituted heteroaralkyl;
- R 2 is alkyl, oxaalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, substituted alkyl, substituted aryl, substituted aralkyl, substituted heteroaryl, and substituted heteroaralkyl;
- R 5 , R 6 , R 7 and R 8 are independently chosen from hydrogen, alkyl, alkoxy, halogen, fluoroalkyl, nitro, dialkylamino, alkylsulfonyl, alkylsulfonamido, sulfonamidoalkyl, sulfonamidoaryl, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, aryl and heretoaryl.
- the process is characterized in that one of the enantiomers, or an enantiomerically enriched mixture, of enantiomers is contacted with an alkali metal alkoxide of a primary alcohol.
- the reaction mixture comprises the primary alcohol from which the alkali metal alkoxide was derived.
- the racemic compounds can then be isolated by conventional methods.
- the alkali metal alkoxide of a primary alcohol will generally be derived from a. primary aliphatic alcohol with 1-6 C-atoms, preferably methanol or ethanol, and more preferably, ethanol.
- the reaction is carried out under reflux temperature.
- FIG. 1 depicts a generic synthetic scheme to make quinazolinone derivatives of Formula I.
- FIG. 2 depicts a synthetic route for the synthesis of quinazolinone derivative
- FIG. 3 depicts a synthetic route to substantially pure single enantiomers.
- FIG. 4 depicts a method for the racemization of quinazolinone derivatives according to one embodiment of the invention.
- Alkyl is intended to include linear, branched, or cyclic hydrocarbon structures and combinations thereof.
- Lower alkyl refers to alkyl groups of from 1 to 5 carbon atoms. Examples of lower alkyl groups include methyl, ethyl, pro pyl, isopropyl, butyl, s-and t-butyl and the like.
- Preferred alkyl groups are those of C 20 or below. More preferred alkyl groups are those of C 13 or below.
- Cycloalkyl is a subset of alkyl and includes cyclic hydrocarbon groups of from 3 to 13 carbon atoms.
- cycloalkyl groups include c-propyl, c-butyl, c-pentyl, norbomyl, and the like.
- alkyl refers to alkanyl, alkenyl and alkynyl residues; it is intended to include cyclohexylmethyl, vinyl, allyl, isoprenyl and the like.
- Alkylene refers to the same residues as alkyl, but having two points of attachment.
- alkylene examples include ethylene (—CH 2 CH 2 —), propylene (—CH 2 CH 2 CH 2 —), dimethylpropylene (—CH 2 C(CH 3 ) 2 CH 2 —) and cyclohexylpropylene (—CH 2 CH 2 CH(C 6 H 13 )—).
- alkyl residue having a specific number of carbons all geometric isomers having that number of carbons are intended to be encompassed; thus, for example, “butyl” is meant to include n-butyl, sec-butyl, isobutyl and t-butyl; “propyl” includes n-propyl and isopropyl.
- Alkoxy or alkoxyl refers to groups of from 1 to 8 carbon atoms of a straight, branched, cyclic configuration and combinations thereof attached to the parent structure through an oxygen. Examples include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy and the like. Lower-alkoxy refers to groups containing one to four carbons.
- Aryl and heteroaryl mean a 5- or 6-membered aromatic or heteroaromatic ring containing 0-3 heteroatoms selected from O, N, or S; a bicyclic 9- or 10-membered aromatic or heteroaromatic ring system containing 0-3 heteroatoms selected from O, N, or S; or a tricyclic 13- or 14-membered aromatic or heteroaromatic ring system containing 0-3 heteroatoms selected from O, N, or S.
- the aromatic 6- to 14-membered carbocyclic rings include, e.g., benzene, naphthalene, indane, tetralin, and the 5- to 10-membered aromatic heterocyclic rings include, e.g., imidazole, pyridine, indole, thiophene, benzopyranone, thiazole, furan, benzimidazole, quinoline, isoquinoline, quinoxaline, pyrimidine, pyrazine, tetrazole and pyrazole.
- Aralkyl refers to a residue in which an aryl moiety is attached to the parent structure via an alkyl residue. Examples are benzyl, phenethyl, phenylvinyl, phenylallyl and the like.
- Oxaalkyl and oxaaralkyl refer to alkyl and aralkyl residues in which one or more methylenes have been replaced by oxygen.
- oxaalkyl and oxaaralkyl residues are ethoxyethoxyethyl (3,6-dioxaoctyl), benzyloxymethyl and phenoxymethyl; in general, glycol ethers, such as polyethyleneglycol, are intended to be encompassed by this group.
- Heteroaralkyl refers to a residue in which a heteroaryl moiety is attached to the parent structure via an alkyl residue. Examples include furanylmethyl, pyridinylmethyl, pyrimidinylethyl and the like.
- Heterocycle means a cycloalkyl or aryl residue in which one to four of the carbons is replaced by a heteroatom such as oxygen, nitrogen or sulfur.
- heterocycles that fall within the scope of the invention include imidazoline, pyrrolidine, pyrazole, pyrrole, indole, quinoline, isoquinoline, tetrahydroisoquinoline, benzofuran, benzodioxan, benzodioxole (commonly referred to as methylenedioxyphenyl, when occurring as a substituent), tetrazole, morpholine, thiazole, pyridine, pyridazine, pyrimidine, thiophene, furan, oxazole, oxazoline, isoxazole, dioxane, tetrahydrofuran and the like.
- N-heterocyclyl refers to a nitrogen-containing heterocycle as a substituent residue.
- the term heterocyclyl encompasses heteroaryl, which is a subset of heterocyclyl.
- Examples of N-heterocyclyl residues include 4-morpholinyl, 4-thiomorpholinyl, 1-piperidinyl, 1-pyrrolidinyl, 3-thiazolidinyl, piperazinyl and 4-(3,4-dihydrobenzoxazinyl).
- substituted heterocyclyl include 4-methyl-1-piperazinyl and 4-benzyl-1-piperidinyl.
- Substituted alkyl, aryl and heteroaryl refer to alkyl, aryl or heteroaryl wherein H atoms are replaced with alkyl, halogen, hydroxy, alkoxy, alkylenedioxy (e.g. methylenedioxy) fluoroalkyl, carboxy (—COOH), carboalkoxy (i.e.
- substituted alkyl also includes oxaalkyl residues, i.e. alkyl residues in which one or more carbons has been replaced by oxygen.
- Halogen refers to fluorine, chlorine, bromine or iodine. Fluorine, chlorine and bromine are preferred.
- Dihaloaryl, dihaloalkyl, trihaloaryl etc. refer to aryl and alkyl substituted with a plurality of halogens, but not necessarily a plurality of the same halogen; thus 4-chloro-3-fluorophenyl is within the scope of dihaloaryl.
- an enantiomer, or an enantiomerically enriched mixture, of an optically active compound will have a formula:
- R 1 is chosen from hydrogen, alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, substituted alkyl, substituted aryl, substituted aralkyl, substituted heteroaryl, and substituted heteroaralkyl;
- R 2 is alkyl, oxaalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, substituted alkyl, substituted aryl, substituted aralkyl, substituted heteroaryl, and substituted heteroaralkyl;
- R 5 , R 6 , R 7 and R 8 are independently chosen from hydrogen, alkyl, alkoxy, halogen, fluoroalkyl, nitro, cyano, dialkylamino, alkylsulfonyl, alkylsulfonamido, sulfonamidoalkyl, sulfonamidoaryl, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, aryl and heretoaryl. See, PCT WO 01/30768.
- These compounds contain one or more asymmetric centers (e.g. the carbon to which R 2 is attached) and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)— or (S)—.
- the quinazolinones of Formula II which are enriched in one optical isomer may be used in the present invention irrespective of the degree of enantiomeric excess of a specific optical isomer contained therein.
- the starting material of the racemization method described herein may be enriched with the R-configuration or the S-configuration. Preferably, it will be enriched with the S-isomer.
- R 1 is selected from hydrogen, alkyl, aryl, substituted alkyl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, and substituted heteroaralkyl.
- R 1 is selected from hydrogen, lower alkyl, substituted lower alkyl, aryl, substituted aryl, aralkyl and substituted aralkyl.
- R 1 is chosen from hydrogen, ethyl, propyl, methoxyethyl, naphthyl, phenyl, bromophenyl, chlorophenyl, methoxyphenyl, ethoxyphenyl, tolyl, dimethylphenyl, chorofluorophenyl, methylchlorophenyl, ethylphenyl, phenethyl, benzyl, chlorobenzyl, methylbenzyl, methoxybenzyl, tetrahydrofuranylmethyl and (ethoxycarbonyl)ethyl.
- R 2 is alkyl or substituted alkyl.
- R 2 is chosen from methyl, ethyl, propyl, methylthioethyl, aminobutyl, (CBZ)aminobutyl, cyclohexylmethyl, benzyloxymethyl, methylsulfinylethyl, methylsulfinylmethyl, hydroxymethyl, benzyl and indolylmethyl.
- R 5 , R 6 , R 7 and R 8 are independently chosen from hydrogen, halogen, methyl, cyano, and trifluoromethyl. More preferably, R 5 is hydrogen or halogen; R 6 , is hydrogen, methyl, or halogen; R 7 is hydrogen, halogen, lower alkyl, substituted lower alkyl, lower alkoxy, or cyano; and/or R 8 is hydrogen or halogen. In another embodiment, embodiment, R 5 , R 6 , and R 8 are hydrogen. More preferably, R 5 , R 6 , and R 8 are hydrogen and R 7 is halogen
- R 1 is chosen from aralkyl or substituted aralkyl; R 2 is lower alkyl; R 5 is hydrogen; R 6 is hydrogen; R 7 is halo or cyano; and R 8 is hydrogen; or R 1 is benzyl or substituted benzyl; R 2 is i-propyl; R 5 is hydrogen; R 6 is hydrogen; R 7 is chloro or cyano; and R 8 is hydrogen; or R 1 is benzyl; R 2 is i-propyl; R 5 is hydrogen; R 6 is hydrogen; R 7 is fluoro; and R 8 is hydrogen, or R 1 is benzyl; R 2 is i-propyl; R 5 is hydrogen; R 6 is hydrogen; R 7 is chloro; and R 8 is hydrogen; or R 1 is benzyl; R 2 is i-propyl; R 5 is hydrogen; R 6 is hydrogen; R 7 is chloro; and R 8 is hydrogen; or R 1 is benzyl; R 2 is i-propyl; R 5 is hydrogen;
- racemization produces a racemic mixture, which can be separated by conventional means such as column chromatography, optical resolution using an optically active acid and the like.
- the methods of the present invention utilize an alkali alkoxide of a C 1 -C 6 primary alcohol to effect the racemization.
- the alkali alkoxide will comprise a sodium or potassium alkoxide. More preferably, it will comprise sodium ethoxide.
- the amount of alkali alkoxide used is not particularly limited, but is usually from about 0.01 to 10 moles, preferably 0.01 to 5 moles, more preferably 0.5 to 2 moles per mole of the quinazolinone derivative. Most preferably, equimolar amounts of the alkali alkoxide and the quinazolinone will be used.
- a C 1 -C 6 primary alcohol will be used as the solvent. More preferably, the solvent will comprise the alcohol from which the alkali alkoxide was derived. Most preferably, the primary alcohol will be methanol or ethanol. Preferably, the racemization reaction will be conducted in anhydrous conditions.
- the reaction mixture may comprise lesser amounts of other solvent including aromatic compounds such as benzene, toluene, ethyl benzene, xylene, and chlorobenzene; hydrocarbons such as hexane, cyclohexane, heptane and isooctane; ethers such as t-butyl methyl ether, isopropyl ether, tetrahydrofuran and dioxane, and mixtures thereof.
- aromatic compounds such as benzene, toluene, ethyl benzene, xylene, and chlorobenzene
- hydrocarbons such as hexane, cyclohexane, heptane and isooctane
- ethers such as t-butyl methyl ether, isopropyl ether, tetrahydrofuran and dioxane, and mixtures thereof.
- the concentration of starting material in the racemization reaction may be varied. In general, the reaction will be conducted at a concentration of about 0.1 to about 5 molar, more preferably at about 0.5 to about 2 molar, and most preferably at about 0.5 molar.
- the racemization reaction usually will be conducted at a temperature of less than 200° C.; more preferably, at a temperature of less than 100° C.; and most preferably, at the reflux (or boiling point) temperature of the reaction mixture.
- racemates The product of the racemization reaction (i.e., the “racemates”) will be less enriched in one optical isomer and thus, will have a decreased degree of enantiomeric excess as compared to the starting material.
- the racemates will be present in about a 1:1 ratio.
- the racemized quinazolinone derivative thus obtained by the present invention can be reused in an optical resolution process to produce the desired enantiomer of the optically active quinazolinone derivative after being subjected to a conventional procedure, for example, hydrolysis or neutralization with acidic water or the like, followed by distillation of the solvent, if necessary.
- the compounds of Formula II can be prepared by following the procedures described with reference to the Reaction Scheme 1 below and by the procedures set forth in the figures and PCT WO 01/30768.
- Step 1 to an optionally substituted benzoic acid (the compound of Formula 101) dissolved in an inert organic solvent (such as THF) in the presence of sodium bicarbonate and a dehydrating agent (such as Na 2 SO 4 ) is added a slight molar excess of an optionally substituted acid chloride (the compound of Formula 102), maintaining about room temperature.
- a dehydrating agent such as Na 2 SO 4
- a slight molar excess of an optionally substituted acid chloride the compound of Formula 102
- Step 3 a compound of Formula 104, dissolved in acetic acid and in the presence of sodium acetate, is heated to 30° C., followed by the addition (with agitation) of a slight molar excess of bromine in acetic acid over a period of 2.5 hours. Completion is monitored, e.g., by TLC; if the starting material continues to be present, temperature is increased to 50° C. until completion.
- the corresponding, optionally substituted quinazolinone of Formula 105 is isolated and purified.
- Step 4 to 1.5 molar equivalents of sodium azide in an inert organic solvent (such as DMF) is slowly added 1 molar equivalent of a compound of Formula 105.
- the reaction takes place with agitation at a temperature of 40° C. over a period of 3 to 10 hours. Completion is monitored, e.g., by TLC.
- the corresponding, optionally substituted quinazolinone azide of Formula 106 is isolated and purified.
- Step 5 to a solution of triphenylphosphine dissolved in an inert organic solvent (such as THF) is added an azide of Formula 106, portionwise over about 15 minutes. The reaction takes place with agitation, maintaining the temperature at 20° C. over a period of 5 minutes to 1 hour. The reaction mixture is acidified, solvents removed followed by conventional work up to give the hydrochloride salt of the corresponding, optionally substituted quinazolinone of Formula 107, which is isolated and purified in the usual manner.
- an inert organic solvent such as THF
- R 2 substituent such as the (R) isomer
- R 2 substituent such as the (R) isomer
- R 2 substituent
- An amine of Formula 107 is dissolved in an inert organic solvent (such as IPA) and warmed to 60° C.
- a resolving agent such as dibenzoyl-D-tartaric acid
- IPA inert organic solvent
- a resolving agent such as dibenzoyl-D-tartaric acid
- the reaction mixture is left to crystallize by cooling to room temperature over 16 hours under continuing agitation.
- the desired isomer e.g., the (R) isomer illustrated as Formula 107a, is isolated and purified in the usual manner.
- the quinazolinone derivative of Formula II can be converted to compounds of Formula I(a), I(b), I(c), or I(d) as described in the Reaction Schemes below and as shown in the figures. See, also, PCT WO 01/30768.
- Step 1 to a solution of a compound of Formula 107 is added successively a slight excess (preferably about 1.2 equivalents) of an aldehyde comprising R 4 (i.e., a compound having the formula R 4 CHO where R 4 CH 2 — is equivalent to R 4 and R 4 is as described above or is a protected precursor to such a substituent, e.g., (3-oxo-propyl)-carbamic acid tert-butyl ester) and a reducing agent such as sodium triacetoxyborohydride.
- R 4 i.e., a compound having the formula R 4 CHO where R 4 CH 2 — is equivalent to R 4 and R 4 is as described above or is a protected precursor to such a substituent, e.g., (3-oxo-propyl)-carbamic acid tert-butyl ester
- a reducing agent such as sodium triacetoxyborohydride
- Step 2 to a solution of a compound of Formula 203 and an amine base such as diisopropylethylamine in a nonpolar, aprotic solvent such as dichloromethane is added an R 3 acyl chloride (such as Cl—C(O)—R 3 where R 3 is as described above). The resulting solution is stirred under nitrogen at room temperature for several hours. The product, a compound of Formula 205 is isolated and purified.
- an acyl chloride such as Cl—C(O)—R 3 where R 3 is as described above.
- any protecting groups on compounds of Formula 205 are then removed.
- R 4 comprises a protected amine wherein the protecting group is a Boc group
- the Boc group can be removed by treatment of the compound of Formula 205 with an acid such as trifluoroacetic acid in a nonpolar, aprotic solvent such as dichloromethane, while maintaining the reaction at about room temperature.
- the reaction is monitored e.g., by TLC.
- a compound of Formula 207 is isolated and purified.
- a compound of Formula 203 is reacted with a slight excess of a compound of the formula R 15 O(CO)Cl in the presence of a base such as triethylamine in a nonpolar, aprotic solvent such as dichloromethane.
- a base such as triethylamine
- a nonpolar, aprotic solvent such as dichloromethane.
- a compound of Formula 203 is treated with a slight excess of an isocyanate R 15 —N ⁇ C ⁇ O in the presence of a base, such as triethylamine, in a nonpolar, aprotic solvent, such as dichloromethane.
- a base such as triethylamine
- a nonpolar, aprotic solvent such as dichloromethane
- EEDQ 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline
- HATU O-(7-Azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
- HMDS hexamethyldisilazane
- NMO N-methylmorpholine oxide
- PPTS pyridinium p-toluenesulfonate
- TFA trifluoroacetic acid
- Trt triphenylmethyl
- Step 1 N-butyryl Anthranilic Acid.
- Step 2 2-Propyl-3,1-[4H]benzoxazin-4-one.
- Step 3 2-Propyl-3-benzylquinazolin4-one.
- Step 4 2-(1′-bromopropyl)-3-benzylquinazolin-4-one.
- Step 5 2-[1′-(N,N-dimethylethylenediamino)propyl]-3-benzylquinazolin-4-one.
- Step 6 2-[1′-(N-4-fluorobenzoyl)-(N,N-dimethylethylenediamino)propyl]-3-benzylquinazolin4-one.
- a stock solution of compound 5 (1.822 g, 5.0 mmol) was prepared in HPLC grade CHCl 3 (0.5 mL).
- a third solution of triethylamine (2.0 mL of 0.5 M) was prepared in HPLC grade 1,2-dichlorethane.
- a 100 ⁇ L aliquot of each solution was pipetted into a glass reaction vessel using a Beckman Biomet 2000 automated liquid dispenser.
- reaction mixture was shaken using a mechanical shaker, sonicated in an ultrasonic water bath, and then incubated overnight at room temperature.
- the mixture was diluted in CHCl 3 (300 ⁇ L) and washed with 5% aqueous NaHCO 3 and water.
- the solvent was removed in vacuo to provide compound 6 (65%).
- the purity of the compound was analyzed by TLC eluted with CH 2 Cl 2 -ethanol-concentrated aqueous NH 3 , 100:10:1.
Abstract
Racemates are obtained from one of the enantiomers, or an enantiomerically enriched mixture, of an optically active quinazolinone derivative by reaction of the compound with an alkali alkoxide of a primary alcohol and isolation of the racemate.
Description
- This application claims priority under 35 U.S.C. §119(e) to U.S. Ser. No. 60/332,148, filed Nov. 20, 2002, which is incorporated by reference in its entirety for all purposes.
- This invention relates to a process for racemizing one of the enantiomers, or an enantiomerically enriched mixture, of an optically active compound. This invention more specifically relates to racemization of quinazolinone derivatives.
- Interest in the medicinal chemistry of quinazoline derivatives was stimulated in the early 1950's with the elucidation of the structure of a quinazoline alkaloid, 3-[β-keto-γ-(3-hydroxy-2-piperidyl)-propyl]-4-quinazolone, from an Asian plant known for its antimalarial properties. In a quest to find additional antimalarial agents, various substituted quinazolines have been synthesized. Of particular import was the synthesis of the derivative 2-methyl-3-o-tolyl-4-(3H)-quinazolinone. This compound, known by the name methaqualone, though ineffective against protozoa, was found to be a potent hypnotic.
- Since the introduction of methaqualone and its discovery as a hypnotic, the pharmacological activity of quinazolinones and related compounds has been investigated. Quinazolinones and derivatives thereof are now known to have a wide variety of biological properties including hypnotic, sedative, analgesic, anticonvulsant, antitussive and anti-inflammatory activities.
- Quinazolinones are among a growing number of therapeutic agents used to treat cell proliferative disorders, including cancer. For example, PCT WO 01/30768, which is incorporated herein by reference in its entirety, describes a pharmaceutical composition containing quinazolinone derivatives which are inhibitors of the mitotic kinesin KSP and are useful in the treatment of cellular proliferative diseases, for example cancer, hyperplasias, restenosis, cardiac hypertrophy, immune disorders and inflammation. Certain of the compounds described therein have the following formula:
- wherein
- R1 is chosen from hydrogen, alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, substituted alkyl, substituted aryl, substituted aralkyl, substituted heteroaryl, and substituted heteroaralkyl;
- R2 and R2′ are independently chosen from hydrogen, alkyl, oxaalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, substituted alkyl, substituted aryl, substituted aralkyl, substituted heteroaryl, and substituted heteroaralkyl; or R2 and R2′ taken together form a 3- to 7-membered ring;
- R3 is chosen from hydrogen, alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, substituted alkyl, substituted aryl, substituted aralkyl, substituted heteroaryl, substituted heteroaralkyl, oxaalkyl, oxaaralkyl, substituted oxaaralkyl, R15O— and R15—NH—;
- R3a is chosen from hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, substituted alkylheteroaryl and R15—NH—;
- R3b is chosen from alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl;
- R4 is chosen from hydrogen, alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, substituted alkyl, substituted aryl, substituted aralkyl, substituted heteroaryl, substituted heteroaralkyl, and R16-alkylene-;
- R5, R6, R7 and R8 are independently chosen from hydrogen, alkyl, alkoxy, halogen, fluoroalkyl, nitro, dialkylamino, alkylsulfonyl, alkylsulfonamido, sulfonamidoalkyl, sulfonamidoaryl, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, aryl and heretoaryl;
- R15 is chosen from alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, substituted alkyl, substituted aryl, substituted aralkyl, substituted heteroaryl, and substituted heteroaralkyl; and
- R16 is chosen from alkoxy, amino, alkylamino, dialkylamino, N-heterocyclyl and substituted N-heterocyclyl.
- These quinazolinone derivatives have an asymmetric carbon atom (i.e., the stereogenic center to which R2 and R2 are attached) that may exist as a racemic mixture of these compounds, i.e., a mixture of both the (+) and (−) or dextro and levo rotary forms. These compounds can be produced as racemates and administered in this form. However, it is known that the physiological utility of racemic mixtures often is focused on one enantiomer, the other having either little or no effect or even diminishing the effect of the active enantiomer.
- A generic synthetic scheme for the preparation of quinazolinone compounds of Formula I(a)-(d) above is described in PCT WO 01/30768 and is shown in FIGS. 1 and 2. An asymmetric synthesis of the quinazolinone compounds of Formula I using optically active reagents is shown in FIG. 3. Disposal of the undesired enantiomer of an intermediate is not environmentally or economically desirable. Thus an efficient method of converting the inactive or undesirable enantiomer into the other usable, desirable enantiomer is a commercially important objective. This invention makes it possible to achieve this objective.
- The references discussed herein are provided solely for their disclosure prior to the filing date of the present application and are each incorporated herein by reference. Nothing herein is to be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior invention.
-
- comprising:
- contacting said compound with an alkali alkoxide of a C1-C6 primary alcohol; and
- isolating the resulting racemic compound,
- wherein
- R1 is chosen from hydrogen, alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, substituted alkyl, substituted aryl, substituted aralkyl, substituted heteroaryl, and substituted heteroaralkyl;
- R2 is alkyl, oxaalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, substituted alkyl, substituted aryl, substituted aralkyl, substituted heteroaryl, and substituted heteroaralkyl; and
- R5, R6, R7 and R8 are independently chosen from hydrogen, alkyl, alkoxy, halogen, fluoroalkyl, nitro, dialkylamino, alkylsulfonyl, alkylsulfonamido, sulfonamidoalkyl, sulfonamidoaryl, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, aryl and heretoaryl.
- The process is characterized in that one of the enantiomers, or an enantiomerically enriched mixture, of enantiomers is contacted with an alkali metal alkoxide of a primary alcohol. Preferably, the reaction mixture comprises the primary alcohol from which the alkali metal alkoxide was derived. The racemic compounds can then be isolated by conventional methods.
- The alkali metal alkoxide of a primary alcohol will generally be derived from a. primary aliphatic alcohol with 1-6 C-atoms, preferably methanol or ethanol, and more preferably, ethanol. Preferably, the reaction is carried out under reflux temperature.
- This invention will be better understood by reference to the following drawings and description, in which the same reference numerals are used to identify like components.
- FIG. 1 depicts a generic synthetic scheme to make quinazolinone derivatives of Formula I.
- FIG. 2 depicts a synthetic route for the synthesis of quinazolinone derivative
- FIG. 3 depicts a synthetic route to substantially pure single enantiomers.
- FIG. 4 depicts a method for the racemization of quinazolinone derivatives according to one embodiment of the invention.
- General
- Before the present methods are described, it is understood that this invention is not limited to the particular methodology, protocols, and reagents described, as these may vary. It is also to he understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the scope of the present invention which will be limited only by the appended claims.
- It must be noted that as used herein and in the appended claims, the singular forms “a”, “an”, and “the” include plural reference unless the context clearly dictates otherwise.
- Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods, devices, and materials are now described.
- Alkyl is intended to include linear, branched, or cyclic hydrocarbon structures and combinations thereof. Lower alkyl refers to alkyl groups of from 1 to 5 carbon atoms. Examples of lower alkyl groups include methyl, ethyl, pro pyl, isopropyl, butyl, s-and t-butyl and the like. Preferred alkyl groups are those of C20 or below. More preferred alkyl groups are those of C13 or below. Cycloalkyl is a subset of alkyl and includes cyclic hydrocarbon groups of from 3 to 13 carbon atoms. Examples of cycloalkyl groups include c-propyl, c-butyl, c-pentyl, norbomyl, and the like. In this application, alkyl refers to alkanyl, alkenyl and alkynyl residues; it is intended to include cyclohexylmethyl, vinyl, allyl, isoprenyl and the like. Alkylene refers to the same residues as alkyl, but having two points of attachment. Examples of alkylene include ethylene (—CH2CH2—), propylene (—CH2CH2CH2—), dimethylpropylene (—CH2C(CH3)2CH2—) and cyclohexylpropylene (—CH2CH2CH(C6H13)—). When an alkyl residue having a specific number of carbons is named, all geometric isomers having that number of carbons are intended to be encompassed; thus, for example, “butyl” is meant to include n-butyl, sec-butyl, isobutyl and t-butyl; “propyl” includes n-propyl and isopropyl.
- Alkoxy or alkoxyl refers to groups of from 1 to 8 carbon atoms of a straight, branched, cyclic configuration and combinations thereof attached to the parent structure through an oxygen. Examples include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy and the like. Lower-alkoxy refers to groups containing one to four carbons.
- Aryl and heteroaryl mean a 5- or 6-membered aromatic or heteroaromatic ring containing 0-3 heteroatoms selected from O, N, or S; a bicyclic 9- or 10-membered aromatic or heteroaromatic ring system containing 0-3 heteroatoms selected from O, N, or S; or a tricyclic 13- or 14-membered aromatic or heteroaromatic ring system containing 0-3 heteroatoms selected from O, N, or S. The aromatic 6- to 14-membered carbocyclic rings include, e.g., benzene, naphthalene, indane, tetralin, and the 5- to 10-membered aromatic heterocyclic rings include, e.g., imidazole, pyridine, indole, thiophene, benzopyranone, thiazole, furan, benzimidazole, quinoline, isoquinoline, quinoxaline, pyrimidine, pyrazine, tetrazole and pyrazole.
- Aralkyl refers to a residue in which an aryl moiety is attached to the parent structure via an alkyl residue. Examples are benzyl, phenethyl, phenylvinyl, phenylallyl and the like. Oxaalkyl and oxaaralkyl refer to alkyl and aralkyl residues in which one or more methylenes have been replaced by oxygen. Examples of oxaalkyl and oxaaralkyl residues are ethoxyethoxyethyl (3,6-dioxaoctyl), benzyloxymethyl and phenoxymethyl; in general, glycol ethers, such as polyethyleneglycol, are intended to be encompassed by this group.
- Heteroaralkyl refers to a residue in which a heteroaryl moiety is attached to the parent structure via an alkyl residue. Examples include furanylmethyl, pyridinylmethyl, pyrimidinylethyl and the like.
- Heterocycle means a cycloalkyl or aryl residue in which one to four of the carbons is replaced by a heteroatom such as oxygen, nitrogen or sulfur. Examples of heterocycles that fall within the scope of the invention include imidazoline, pyrrolidine, pyrazole, pyrrole, indole, quinoline, isoquinoline, tetrahydroisoquinoline, benzofuran, benzodioxan, benzodioxole (commonly referred to as methylenedioxyphenyl, when occurring as a substituent), tetrazole, morpholine, thiazole, pyridine, pyridazine, pyrimidine, thiophene, furan, oxazole, oxazoline, isoxazole, dioxane, tetrahydrofuran and the like. “N-heterocyclyl” refers to a nitrogen-containing heterocycle as a substituent residue. The term heterocyclyl encompasses heteroaryl, which is a subset of heterocyclyl. Examples of N-heterocyclyl residues include 4-morpholinyl, 4-thiomorpholinyl, 1-piperidinyl, 1-pyrrolidinyl, 3-thiazolidinyl, piperazinyl and 4-(3,4-dihydrobenzoxazinyl). Examples of substituted heterocyclyl include 4-methyl-1-piperazinyl and 4-benzyl-1-piperidinyl.
- Substituted alkyl, aryl and heteroaryl refer to alkyl, aryl or heteroaryl wherein H atoms are replaced with alkyl, halogen, hydroxy, alkoxy, alkylenedioxy (e.g. methylenedioxy) fluoroalkyl, carboxy (—COOH), carboalkoxy (i.e. acyloxy RCOO—), carboxyalkyl (—COOR), carboxamido, sulfonamidoalkyl, sulfonamidoaryl, aminocarbonyl, benzyloxycarbonylamino (CBZ-amino), cyano, carbonyl, nitro, dialkylamino, alkylamino, amino, alkylthio, alkylsulfinyl, alkylsulfonyl, alkylsulfonamido, arylthio, arylsulfinyl, arylsulfonyl, amidino, phenyl, benzyl, heteroaryl, heterocyclyl, phenoxy, benzyloxy, or heteroaryloxy. For the purposes of the present invention, substituted alkyl also includes oxaalkyl residues, i.e. alkyl residues in which one or more carbons has been replaced by oxygen.
- Halogen refers to fluorine, chlorine, bromine or iodine. Fluorine, chlorine and bromine are preferred. Dihaloaryl, dihaloalkyl, trihaloaryl etc. refer to aryl and alkyl substituted with a plurality of halogens, but not necessarily a plurality of the same halogen; thus 4-chloro-3-fluorophenyl is within the scope of dihaloaryl.
- Starting Materials
-
- wherein
- R1 is chosen from hydrogen, alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, substituted alkyl, substituted aryl, substituted aralkyl, substituted heteroaryl, and substituted heteroaralkyl;
- R2 is alkyl, oxaalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, substituted alkyl, substituted aryl, substituted aralkyl, substituted heteroaryl, and substituted heteroaralkyl; and
- R5, R6, R7 and R8 are independently chosen from hydrogen, alkyl, alkoxy, halogen, fluoroalkyl, nitro, cyano, dialkylamino, alkylsulfonyl, alkylsulfonamido, sulfonamidoalkyl, sulfonamidoaryl, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, aryl and heretoaryl. See, PCT WO 01/30768.
- These compounds contain one or more asymmetric centers (e.g. the carbon to which R2 is attached) and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)— or (S)—. The quinazolinones of Formula II which are enriched in one optical isomer may be used in the present invention irrespective of the degree of enantiomeric excess of a specific optical isomer contained therein. Thus, the starting material of the racemization method described herein may be enriched with the R-configuration or the S-configuration. Preferably, it will be enriched with the S-isomer.
- Preferably, R1 is selected from hydrogen, alkyl, aryl, substituted alkyl, substituted aryl, heteroaryl, substituted heteroaryl, aralkyl, substituted aralkyl, and substituted heteroaralkyl.
- In a more preferred embodiment R1 is selected from hydrogen, lower alkyl, substituted lower alkyl, aryl, substituted aryl, aralkyl and substituted aralkyl. In a most preferred embodiment R1 is chosen from hydrogen, ethyl, propyl, methoxyethyl, naphthyl, phenyl, bromophenyl, chlorophenyl, methoxyphenyl, ethoxyphenyl, tolyl, dimethylphenyl, chorofluorophenyl, methylchlorophenyl, ethylphenyl, phenethyl, benzyl, chlorobenzyl, methylbenzyl, methoxybenzyl, tetrahydrofuranylmethyl and (ethoxycarbonyl)ethyl.
- In a preferred embodiment R2 is alkyl or substituted alkyl. In a most preferred embodiment R2 is chosen from methyl, ethyl, propyl, methylthioethyl, aminobutyl, (CBZ)aminobutyl, cyclohexylmethyl, benzyloxymethyl, methylsulfinylethyl, methylsulfinylmethyl, hydroxymethyl, benzyl and indolylmethyl.
- Preferably, R5, R6, R7 and R8 are independently chosen from hydrogen, halogen, methyl, cyano, and trifluoromethyl. More preferably, R5 is hydrogen or halogen; R6, is hydrogen, methyl, or halogen; R7 is hydrogen, halogen, lower alkyl, substituted lower alkyl, lower alkoxy, or cyano; and/or R8 is hydrogen or halogen. In another embodiment, embodiment, R5, R6, and R8 are hydrogen. More preferably, R5, R6, and R8 are hydrogen and R7 is halogen
- In a particularly preferred subgenus, R1 is chosen from aralkyl or substituted aralkyl; R2 is lower alkyl; R5 is hydrogen; R6 is hydrogen; R7 is halo or cyano; and R8 is hydrogen; or R1 is benzyl or substituted benzyl; R2 is i-propyl; R5 is hydrogen; R6 is hydrogen; R7 is chloro or cyano; and R8 is hydrogen; or R1 is benzyl; R2 is i-propyl; R5 is hydrogen; R6 is hydrogen; R7 is fluoro; and R8 is hydrogen, or R1 is benzyl; R2 is i-propyl; R5 is hydrogen; R6 is hydrogen; R7 is chloro; and R8 is hydrogen; or R1 is benzyl; R2 is i-propyl; R5 is hydrogen; R6 is hydrogen; R7 is cyano; and R8 is hydrogen; or R1 is benzyl or halobenzyl; R2 is chosen from ethyl and propyl; R5 is hydrogen; R6 is hydrogen; R7 is halo; and R8 is hydrogen.
- The Racemization Methods
- In the racemization method of the present invention, racemization produces a racemic mixture, which can be separated by conventional means such as column chromatography, optical resolution using an optically active acid and the like.
- The methods of the present invention utilize an alkali alkoxide of a C1-C6 primary alcohol to effect the racemization. Preferably, the alkali alkoxide will comprise a sodium or potassium alkoxide. More preferably, it will comprise sodium ethoxide.
- The amount of alkali alkoxide used is not particularly limited, but is usually from about 0.01 to 10 moles, preferably 0.01 to 5 moles, more preferably 0.5 to 2 moles per mole of the quinazolinone derivative. Most preferably, equimolar amounts of the alkali alkoxide and the quinazolinone will be used.
- Preferably, a C1-C6 primary alcohol will be used as the solvent. More preferably, the solvent will comprise the alcohol from which the alkali alkoxide was derived. Most preferably, the primary alcohol will be methanol or ethanol. Preferably, the racemization reaction will be conducted in anhydrous conditions.
- The reaction mixture may comprise lesser amounts of other solvent including aromatic compounds such as benzene, toluene, ethyl benzene, xylene, and chlorobenzene; hydrocarbons such as hexane, cyclohexane, heptane and isooctane; ethers such as t-butyl methyl ether, isopropyl ether, tetrahydrofuran and dioxane, and mixtures thereof.
- The concentration of starting material in the racemization reaction may be varied. In general, the reaction will be conducted at a concentration of about 0.1 to about 5 molar, more preferably at about 0.5 to about 2 molar, and most preferably at about 0.5 molar.
- The racemization reaction usually will be conducted at a temperature of less than 200° C.; more preferably, at a temperature of less than 100° C.; and most preferably, at the reflux (or boiling point) temperature of the reaction mixture.
- The product of the racemization reaction (i.e., the “racemates”) will be less enriched in one optical isomer and thus, will have a decreased degree of enantiomeric excess as compared to the starting material. Preferably, the racemates will be present in about a 1:1 ratio.
- The racemized quinazolinone derivative thus obtained by the present invention can be reused in an optical resolution process to produce the desired enantiomer of the optically active quinazolinone derivative after being subjected to a conventional procedure, for example, hydrolysis or neutralization with acidic water or the like, followed by distillation of the solvent, if necessary.
- Synthesis of Compounds of Formula II
-
- Preparation of Formula 103
- Referring to
Reaction Scheme 1,Step 1, to an optionally substituted benzoic acid (the compound of Formula 101) dissolved in an inert organic solvent (such as THF) in the presence of sodium bicarbonate and a dehydrating agent (such as Na2SO4) is added a slight molar excess of an optionally substituted acid chloride (the compound of Formula 102), maintaining about room temperature. Completion of the reaction is monitored, e.g., by TLC. Acetic anhydride is then added to the reaction mixture, which is heated to about 90-100° C., monitoring completion of the reaction (e.g., by TLC) followed by removal of the acetic anhydride under vacuum at about 80-100° C. The reaction mixture is cooled and the corresponding, optionally substituted benzo[d][1,3]oxazin-4-one (the compound of Formula 103) is isolated and purified. - Preparation of Formula 104
- Referring to
Reaction Scheme 1,Step 2, about 1.5 molar equivalents of a primary amine (such as R1NH2) and 1 molar equivalent of a compound of Formula 103 in an inert organic solvent (such as toluene) are heated to reflux. The reaction takes place over a period of 1 to 5 hours. After removal of water, ethylene glycol and sodium hydroxide are added to the reaction mixture and the temperature raised to 110-120° C. Completion of the reaction is monitored, e.g., by TLC. The corresponding, optionally substituted quinazolinone (a compound of Formula 104) is isolated and purified. - Preparation of Formula 105
- Referring to
Reaction Scheme 1,Step 3, a compound of Formula 104, dissolved in acetic acid and in the presence of sodium acetate, is heated to 30° C., followed by the addition (with agitation) of a slight molar excess of bromine in acetic acid over a period of 2.5 hours. Completion is monitored, e.g., by TLC; if the starting material continues to be present, temperature is increased to 50° C. until completion. The corresponding, optionally substituted quinazolinone of Formula 105 is isolated and purified. - Preparation of Formula 106
- Referring to
Reaction Scheme 1,Step 4, to 1.5 molar equivalents of sodium azide in an inert organic solvent (such as DMF) is slowly added 1 molar equivalent of a compound of Formula 105. The reaction takes place with agitation at a temperature of 40° C. over a period of 3 to 10 hours. Completion is monitored, e.g., by TLC. The corresponding, optionally substituted quinazolinone azide of Formula 106 is isolated and purified. - Preparation of Formula 107
- Referring to
Reaction Scheme 1,Step 5, to a solution of triphenylphosphine dissolved in an inert organic solvent (such as THF) is added an azide of Formula 106, portionwise over about 15 minutes. The reaction takes place with agitation, maintaining the temperature at 20° C. over a period of 5 minutes to 1 hour. The reaction mixture is acidified, solvents removed followed by conventional work up to give the hydrochloride salt of the corresponding, optionally substituted quinazolinone of Formula 107, which is isolated and purified in the usual manner. - Preparation of Formula 107a
- In certain compounds of the invention, particular stereoconfiguration can be preferred for the R2 substituent, such as the (R) isomer, which can be obtained, e.g., as illustrated in optional Step 5a of
Reaction Scheme 1. An amine of Formula 107 is dissolved in an inert organic solvent (such as IPA) and warmed to 60° C. In a separate vessel, a resolving agent (such as dibenzoyl-D-tartaric acid) is dissolved, preferably in the same warm solvent, and then quickly added (with agitation) to the warm amine solution. The reaction mixture is left to crystallize by cooling to room temperature over 16 hours under continuing agitation. The desired isomer, e.g., the (R) isomer illustrated as Formula 107a, is isolated and purified in the usual manner. - Synthesis of Compounds of Formula I
-
- Preraration of Formula 203
- Refering to
Reaction Scheme 2,Step 1, to a solution of a compound of Formula 107 is added successively a slight excess (preferably about 1.2 equivalents) of an aldehyde comprising R4 (i.e., a compound having the formula R4CHO where R4CH2— is equivalent to R4 and R4 is as described above or is a protected precursor to such a substituent, e.g., (3-oxo-propyl)-carbamic acid tert-butyl ester) and a reducing agent such as sodium triacetoxyborohydride. The resulting mixture is stirred for several hours. The product, a compound of Formula 203 is isolated and purified. - Preparation of Formula 205
- Referring to
Reaction Scheme 2,Step 2, to a solution of a compound of Formula 203 and an amine base such as diisopropylethylamine in a nonpolar, aprotic solvent such as dichloromethane is added an R3 acyl chloride (such as Cl—C(O)—R3 where R3 is as described above). The resulting solution is stirred under nitrogen at room temperature for several hours. The product, a compound of Formula 205 is isolated and purified. - Preparation of Formula 207
-
- Referring to
Reaction Scheme 3, to a solution of a compound of Formula 203 and an amine base such as diisopropylethylamine in a nonpolar, aprotic solvent such as dichloromethane is added a compound having the formula Cl—S(O)2—R3a or O—(S(O)2—R3a)2 where R3a is as described above. The resulting solution is stirred under nitrogen at room temperature for several hours. The product, a compound of Formula 303 is isolated and purified. - Referring to
Reaction Scheme 4, to a solution of a compound of Formula 203 and an amine base such as diisopropylethylamine in a nonpolar, aprotic solvent such as dichloromethane is added a compound having the formula Cl—CH2—R3b where R3b is as described above. The resulting solution is stirred under nitrogen at room temperature or with heat for several hours. The product, a compound of Formula 403 is isolated and purified. -
- Referring to
Reaction Scheme 6, a compound of Formula 203 is treated with a slight excess of an isocyanate R15—N═C═O in the presence of a base, such as triethylamine, in a nonpolar, aprotic solvent, such as dichloromethane. The product, a compound of Formula 603, is isolated and purified. - The following examples are given to enable those skilled in the art to more clearly understand and to practice the present invention. They should not be considered as limiting the scope of the invention, but merely as being illustrative and representative thereof.
- The following abbreviations and terms have the indicated meanings throughout:
- Ac=acetyl
- Boc=t-butyloxy carbonyl
- Bu=butyl
- c-=cyclo
- CBZ=carbobenzoxy=benzyloxycarbonyl
- DBU=diazabicyclo[5.4.0]undec-7-ene
- DCM=dichloromethane=methylene chloride=CH2Cl2
- DCE=dichloroethylene
- DEAD=diethyl azodicarboxylate
- DIC=diisopropylcarbodiimide
- DIEA=N,N-diisopropylethyl amine
- DMAP=4-N,N-dimethylaminopyridine
- DMF=N,N-dimethylformamide
- DMSO=dimethyl sulfoxide
- DVB=1,4-divinylbenzene
- EEDQ=2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline
- Et=ethyl
- Fmoc=9-fluorenylmethoxycarbonyl
- GC=gas chromatography
- HATU=O-(7-Azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
- HMDS=hexamethyldisilazane
- HOAc=acetic acid
- HOBt=hydroxybenzotriazole
- Me=methyl
- mesyl=methanesulfonyl
- MTBE=methyl t-butyl ether
- NMO=N-methylmorpholine oxide
- PEG=polyethylene glycol
- Ph=phenyl
- PhOH=phenol
- PfP=pentafluorophenol
- PPTS=pyridinium p-toluenesulfonate
- Py=pyridine
- PyBroP=bromo-tris-pyrrolidino-phosphonium hexafluorophosphate
- rt=room temperature
- sat=d=saturated
- s-=secondary
- t-=tertiary
- TBDMS=t-butyldimethylsilyl
- TES=triethylsilane
- TFA=trifluoroacetic acid
- THF=tetrahydrofuran
- TMOF=trimethyl orthoformate
- TMS=trimethylsilyl
- tosyl=p-toluenesulfonyl
- Trt=triphenylmethyl
- The general synthesis is shown in FIGS. 1 and 2 and is described further above.
- Step 1: N-butyryl Anthranilic Acid.
- To a three-necked, 500 mL round-bottom flask equipped with a thermometer, dropping funnel, and an efficient magnetic stir bar, was added anthranilic acid (1) (0.5 mole, 68.5 g) and dimethyl formamide (250 mL). To this solution was added butyryl chloride (0.55 mole, 57.1 mL) dropwise at such a rate that the temperature of the mixture did not rise above 40° C. The suspension was stirred vigorously at room temperature for at least an additional 3 h. The mixture was poured into water (2000 mL) and stirred for another 1 h. The precipitated product was collected by filtration, washed with cold water, and dried under reduced pressure over P2O5, yielding compound 2 (67.3 g, 65%).
- Step 2: 2-Propyl-3,1-[4H]benzoxazin-4-one.
- Compound 2 (51.8 g, 0.25 mole) was dissolved in acetic anhydride (180 mL) in a 500 mL round-bottom flask equipped with a magnetic stir bar, a Claisen-distillation head (with vacuum inlet) and a thermometer. The flask was placed in an oil bath and slowly heated to 170-180° C. with vigorous stirring. The acetic acid produced was slowly distilled off under atmospheric pressure. Monitoring the head temperature of the distillation unit was used to follow the progress of the transformation. The reaction mixture was then cooled to 60° C. and the excess of acetic anhydride removed by distillation under reduced pressure (ca. 20 mm Hg). The residue was afterward cooled and the product crystallized. The product was triturated with n-hexane (75 mL) and isolated by filtration to yield 2-propyl-3,1-[4H]benzoxazin-4-one (3) (29.3 g, 62%). The above procedure gave
compound 3 sufficiently pure to use directly in the next step. - Step 3: 2-Propyl-3-benzylquinazolin4-one.
- Compound 3 (28.4 g, 0.15 mole) and benzylamine (17.5 mL, 0.16 mole) were refluxed in chloroform (50 ml) in a one-neck 250 mL round-bottom flask for 6 h. After complete consumption of
compound 3, the chloroform was evaporated under reduced pressure. Ethylene glycol (100 mL) and NaOH pellets (0.60 g) were added to the residue and the flask equipped with a Claisen-distillation head and a magnetic stir bar. The flask was immersed in an oil bath and reheated to 130-140° C. bath temperature with vigorous stirring and maintained there for 5 h while the water produced was removed by distillation. After completion of the reaction, the clear solution was allowed to cool to room temperature and kept overnight to precipitate the product. The pH of the suspension was adjusted to 7-8 by adding 3% aq. HCl, the crystals were filtered off and washed with cold water, and then recrystallized from isopropanol (or alternatively from acetone) to provide the compound, 2-propyl-3-benzylquinazolin-4-one (compound 4) (28.0 g, 67%). - Step 4: 2-(1′-bromopropyl)-3-benzylquinazolin-4-one.
- To a three-neck 250 mL round-bottom flask equipped with a thermometer, dropping funnel, and efficient magnetic stir bar was added compound 4 (27.8 g, 0. 10 mole), anhydrous sodium acetate (10.0 g) and glacial acetic acid (130 mL). Bromine (16.0 g, 0.10 mole) dissolved in acetic acid (10 mL) was added dropwise to the above solution at 40 ° C. for 1-2 h. After addition was complete, the mixture was poured into water (1500 mL) and stirred for 1-2 h at room temperature. The precipitated product, 2-(1′-bromopropyl)-3-benzylquinazolin-4-one (5) was isolated by filtration, washed with warm water to remove traces of acetic acid, and rinsed with a small amount of isopropanol. Drying yielded compound 5 (33.0 g, 92%).
- Step 5: 2-[1′-(N,N-dimethylethylenediamino)propyl]-3-benzylquinazolin-4-one.
- Compound 5 (10.7 g, 0.03 mole) and N,N-dimethylethylenediamine (6.6 mL, 0.06 mole) were dissolved in abs. ethanol (60 mL) and heated at reflux for 6 h. After completion of the reaction, the solvent was evaporated under reduced pressure. The residue was dissolved in dichloromethane (150 mL) and washed with 3% aq. NaOH solution (ca. 10-20 mL). The organic layer was dried over MgSO4 and evaporated to dryness under reduced pressure. The remaining oily product was purified by flash chromatography on a short silica gel pad using an eluent of CHCl3—MeOH-aq.NH3, 90:10:0.1, to give the desired compound (5), 2-[1′-(N,N-dimethylethylenediamino)propyl]-3-benzylquinazolin-4-one (6) (6.0 g, 55%).
- Step 6: 2-[1′-(N-4-fluorobenzoyl)-(N,N-dimethylethylenediamino)propyl]-3-benzylquinazolin4-one.
- A stock solution of compound 5 (1.822 g, 5.0 mmol) was prepared in HPLC grade CHCl3 (0.5 mL). A stock solution of p-fluorobenzoyl chloride (160.2 mg, 1 mmol) in
HPLC grade 1,2-dichloroethane (2.0 mL) was prepared in a 2.0 mL volumetric flask. A third solution of triethylamine (2.0 mL of 0.5 M) was prepared inHPLC grade 1,2-dichlorethane. A 100 μL aliquot of each solution was pipetted into a glass reaction vessel using a Beckman Biomet 2000 automated liquid dispenser. The reaction mixture was shaken using a mechanical shaker, sonicated in an ultrasonic water bath, and then incubated overnight at room temperature. The mixture was diluted in CHCl3 (300 μL) and washed with 5% aqueous NaHCO3 and water. The solvent was removed in vacuo to provide compound 6 (65%). The purity of the compound was analyzed by TLC eluted with CH2Cl2-ethanol-concentrated aqueous NH3, 100:10:1. -
- The S-isomer of the compound shown in FIG. 4, wherein R1 is benzyl; R2 is isopropyl; R5, R6, and R8 are hydrogen; and R7 is chloro, (490 mg, 1.44 mmol) and sodium ethoxide (0.535 mL of a 21% by weight solution in denatured alcohol containing 5% toluene; 1.64 mmol) were dissolved in abs. ethanol (2.5 mL) and heated at reflux for 36 h. After completion of the reaction, the solvent was evaporated under reduced pressure. The residue was dissolved in dichloromethane and washed with 2N aq. HCl solution which was added dropwise until the solution had a pH of about 7. The organic layer was dried over Na2SO4 and evaporated to dryness under reduced pressure. The remaining product (478 mg, 86% pure by NMR) comprised a 1:1.1 mixture of the R- and S-isomers as shown by chiral liquid chromatography.
- While the present invention has been described with reference to the specific embodiments thereof, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process step or steps, to the objective, spirit and scope of the present invention. All such modifications are intended to be within the scope of the claims appended hereto. All patents and publications cited above are hereby incorporated by reference.
Claims (12)
1-13. (canceled)
14. A method for making an enantiomer, or an enantiomerically enriched mixture of a compound of the formula
wherein said method comprises the steps of:
contacting an enantiomer, or an enantiomerically enriched mixture of a starting compound of formula
with an alkali alkoxide in a C1-C6 primary alcohol at a selected racemization reaction temperature whereby said enantiomer or enantiomerically enriched mixture is racemized to yield a racemic mixture;
isolating the racemic mixture;
subjecting said racemic mixture to an optical resolution process whereby the racemic mixture is separated into its corresponding stereoisomers; and
converting desired stereoisomer to said compound using an acid chloride of the formula R3—C(O)—Cl
wherein
R1 is selected from the group consisting of hydrogen, alkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl;
R2 and R2′ are independently selected from the group consisting of alkyl, oxaalkyl, aryl, alkylaryl, heteroaryl, alkylheteroaryl, substituted alkyl, substituted aryl, substituted alkylaryl, substituted heteroaryl, and substituted alkylheteroaryl;
R3 is selected from the group consisting of hydrogen, alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, substituted alkyl, substituted aryl, substituted aralkyl, substituted heteroaryl, substituted heteroaralkyl, oxaalkyl, oxaaralkyl, substituted oxaaralkyl, R15O— and R15—NH—;
R4 is selected from the group consisting of hydrogen, alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, substituted alkyl, substituted aryl, substituted aralkyl, substituted heteroaryl, substituted heteroaralkyl, and R16-alkylene-;
R5, R6, R7, R8 are independently selected from the group consisting of hydrogen, alkyl, alkoxy, halogen, fluoralkyl, nitro, dialkylamino, alkylsulfonyl, alkylsulfonamido, sulfonamidoalkyl, sulfonamidoaryl, alkylthio, carboxyalkyl, carboxamido, aminocarbonyl, aryl and heteroaryl;
R15 is selected from the group consisting of alkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, substituted alkyl, substituted aryl, substituted aralkyl, substituted heteroaryl, and substituted heteroaralkyl; and
R16 is selected from the group consisting of alkoxy, amino, alkylamino, dialkylamino, N-heterocyclyl and substituted heterocyclyl.
15. The method of claim 14 , wherein the C1-C6 primary alcohol is ethanol.
16. The method of claim 14 , wherein the alkali alkoxide is a sodium or potassium alkoxide.
17. The method of claim 14 , wherein the alkali alkoxide is sodium ethoxide.
18. The method of claim 14 , wherein the racemization reaction temperature is less than 200° C.
19. The method of claim 14 , wherein the racemization reaction temperature is less than 100° C.
20. The method of claim 14 , wherein the racemization reaction temperature is at the boiling point of the reaction mixture.
21. The method of claim 14 , wherein the enantiomer has an R-configuration.
22. The method of claim 14 , wherein the enantiomer has an S-configuration.
23. The method of claim 14 , wherein the alkali alkoxide is derived from an alkali metal and a C1-C6 primary alcohol.
24. The method of claim 23 , wherein the C1-C6 primary alcohol is methanol or ethanol.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/773,602 US20040192913A1 (en) | 2001-11-20 | 2004-02-06 | Process for the racemization of chiral quinazolinones |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33214801P | 2001-11-20 | 2001-11-20 | |
US10/300,967 US6753428B2 (en) | 2001-11-20 | 2002-11-20 | Process for the racemization of chiral quinazolinones |
US10/773,602 US20040192913A1 (en) | 2001-11-20 | 2004-02-06 | Process for the racemization of chiral quinazolinones |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/300,967 Continuation US6753428B2 (en) | 2001-11-20 | 2002-11-20 | Process for the racemization of chiral quinazolinones |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040192913A1 true US20040192913A1 (en) | 2004-09-30 |
Family
ID=23296908
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/300,967 Expired - Fee Related US6753428B2 (en) | 2001-11-20 | 2002-11-20 | Process for the racemization of chiral quinazolinones |
US10/773,602 Abandoned US20040192913A1 (en) | 2001-11-20 | 2004-02-06 | Process for the racemization of chiral quinazolinones |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/300,967 Expired - Fee Related US6753428B2 (en) | 2001-11-20 | 2002-11-20 | Process for the racemization of chiral quinazolinones |
Country Status (3)
Country | Link |
---|---|
US (2) | US6753428B2 (en) |
AU (1) | AU2002346471A1 (en) |
WO (1) | WO2003043995A1 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040067969A1 (en) * | 2002-02-15 | 2004-04-08 | Gustave Bergnes | Syntheses of quinazolinones |
US20040077662A1 (en) * | 2002-05-09 | 2004-04-22 | Cytokinetics, Inc. | Compounds, methods and compositions |
US20040077668A1 (en) * | 2002-05-09 | 2004-04-22 | Cytokinetics, Inc. | Compounds, compositins, and methods |
US20040082567A1 (en) * | 2002-06-14 | 2004-04-29 | Cytokinetics, Inc. | Compounds, compositions, and methods |
US20040254203A1 (en) * | 1999-10-27 | 2004-12-16 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
US20050148593A1 (en) * | 2003-11-07 | 2005-07-07 | Gustave Bergnes | Compounds, compositions, and methods |
US20050234037A1 (en) * | 2003-12-08 | 2005-10-20 | Gustave Bergnes | Compounds, compositions, and methods |
US20060264449A1 (en) * | 2002-09-30 | 2006-11-23 | Gustave Bergnes | Compounds, compositions, and methods |
US20070254902A1 (en) * | 1999-10-27 | 2007-11-01 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
US20080182864A1 (en) * | 1999-10-27 | 2008-07-31 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7038048B2 (en) * | 2002-05-23 | 2006-05-02 | Cytokinetics, Inc. | 3H-pyridopyrimidin-4-one compounds, compositions, and methods of their use |
AU2003256805A1 (en) * | 2002-07-23 | 2004-02-09 | Cytokinetics, Inc. | Compounds compositions and methods |
AU2003262747A1 (en) * | 2002-08-21 | 2004-03-11 | Cytokinetics, Inc. | Compounds, compositions, and methods |
WO2006018628A1 (en) * | 2003-03-07 | 2006-02-23 | Astrazeneca Ab | Enantiomers of selected fused pyrimidones and uses in the treatment and preventi on of cancer |
WO2004078758A1 (en) * | 2003-03-07 | 2004-09-16 | Astrazeneca Ab | Novel fused heterocycles and uses thereof |
EP1682534A2 (en) * | 2003-11-03 | 2006-07-26 | Cytokinetics, Inc. | Pyrimidin-4-one compounds, compositions, and methods |
WO2005095360A1 (en) | 2004-04-02 | 2005-10-13 | Prana Biotechnology Limited | Neurologically-active compounds |
PL1753723T3 (en) | 2004-05-21 | 2009-01-30 | Novartis Vaccines & Diagnostics Inc | Substituted quinoline derivatives as mitotic kinesin inhibitors |
US20050282834A1 (en) * | 2004-06-09 | 2005-12-22 | Fady Malik | Compositions, devices and methods for treating cardiovascular disease |
AU2005258135B2 (en) | 2004-06-18 | 2011-09-22 | Novartis Vaccines And Diagnostics Inc. | N- (1- (1-benzyl -4-phenyl-1H-imidazol-2-YL) -2,2-dymethylpropyl) benzamide derivatives and related compounds as kinesin spindle protein (KSP) inhibitors for the treatment of cancer |
EP1773830A1 (en) * | 2004-07-22 | 2007-04-18 | AstraZeneca AB | Fused pyrimidones useful in the treatment and the prevention of cancer |
US20060041128A1 (en) * | 2004-08-18 | 2006-02-23 | Astrazeneca Ab | Selected fused heterocyclics and uses thereof |
CA2575188A1 (en) * | 2004-08-18 | 2006-02-23 | Astrazeneca Ab | Enantiomers of selected fused pyrimidones and uses in the treatment and preventi on of cancer |
CN101233115A (en) | 2004-10-19 | 2008-07-30 | 诺华疫苗和诊断公司 | Indole and benzimidazole derivatives |
WO2006060737A2 (en) * | 2004-12-03 | 2006-06-08 | Takeda San Diego, Inc. | Mitotic kinesin inhibitors |
CA2668661A1 (en) | 2006-11-13 | 2008-05-29 | Novartis Ag | Substituted pyrazole and triazole compounds as ksp inhibitors |
EP2106399A2 (en) | 2007-01-05 | 2009-10-07 | Novartis AG | Imidazole derivatives as kinesin spindle protein inhibitors (eg-5) |
BRPI0813355A2 (en) | 2007-06-22 | 2014-12-30 | Arqule Inc | QUINAZOLINONE COMPOUNDS AND METHODS OF USE THEREOF |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CN103420921A (en) * | 2013-08-07 | 2013-12-04 | 浙江大学 | Method for synthesizing optically-active 2,3-dihydro quinazolinone derivative by using chiral spiro phosphoric acid as catalyst |
WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
PL3052485T3 (en) | 2013-10-04 | 2022-02-28 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CA2943075C (en) | 2014-03-19 | 2023-02-28 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
WO2017003723A1 (en) | 2015-07-01 | 2017-01-05 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
MX2018003058A (en) | 2015-09-14 | 2018-08-01 | Infinity Pharmaceuticals Inc | Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same. |
WO2017161116A1 (en) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US11028068B2 (en) | 2017-07-25 | 2021-06-08 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
CN108445033B (en) * | 2018-01-16 | 2020-01-31 | 温州大学 | Determination method for optical purity of alkaloids of 4- (3H) quinazolinone compounds |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6794379B2 (en) * | 2001-06-06 | 2004-09-21 | Tularik Inc. | CXCR3 antagonists |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1249281B (en) | 1963-05-18 | |||
US3320124A (en) | 1964-07-20 | 1967-05-16 | American Cyanamid Co | Method for treating coccidiosis with quinazolinones |
BG16042A3 (en) | 1968-11-12 | 1972-05-20 | Nans Ott | METHOD FOR OBTAINING NEW 2(1H)-QUINAZOLINONES |
US3740442A (en) | 1972-01-14 | 1973-06-19 | Sandoz Ag | 2-isopropylaminobenzophenones in treating inflammation |
AU543928B2 (en) | 1981-01-16 | 1985-05-09 | Masayuki Ishikawa | 4(311)-quinazolinone derivatives |
GB8607683D0 (en) | 1986-03-27 | 1986-04-30 | Ici Plc | Anti-tumor agents |
US5187167A (en) | 1986-03-27 | 1993-02-16 | Imperial Chemical Industries Plc | Pharmaceutical compositions comprising quinazolin-4-one derivatives |
US4729996A (en) | 1986-05-29 | 1988-03-08 | Harbor Branch Oceanographic Institution, Inc. | Antitumor compositions and their methods of use |
DE3721855A1 (en) | 1987-03-12 | 1988-09-22 | Merck Patent Gmbh | AMINO ACID DERIVATIVES |
GB8707053D0 (en) | 1987-03-25 | 1987-04-29 | Ici Plc | Anti-tumour agents |
US4866084A (en) | 1987-07-17 | 1989-09-12 | Harbor Branch Oceanographic Institution, Inc. | Topsentin compounds effective against viruses and certain tumors |
US4808590A (en) | 1987-07-17 | 1989-02-28 | Harbor Branch Oceanographic Institution, Inc. | Antiviral, antitumor and antifungal compositions and their methods of use |
US5756450A (en) | 1987-09-15 | 1998-05-26 | Novartis Corporation | Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms |
US4857530A (en) | 1987-11-03 | 1989-08-15 | Warner-Lambert Company | Substituted quinazolinones as anticancer agents |
GB8820129D0 (en) | 1988-08-24 | 1988-09-28 | Schering Agrochemicals Ltd | Fungicides |
GB8827820D0 (en) | 1988-11-29 | 1988-12-29 | Janssen Pharmaceutica Nv | (1h-azol-1-ylmethyl)substituted quinoline derivatives |
GB8827988D0 (en) | 1988-11-30 | 1989-01-05 | Smith Kline French Lab | Chemical compounds |
US4970226A (en) | 1989-10-03 | 1990-11-13 | Harbor Branch Oceanographic Institution, Inc. | Bis-indole imidazole compounds which are useful antitumor and antimicrobial agents |
IL98167A0 (en) | 1990-05-30 | 1992-06-21 | Ici Plc | Anti-tumour quinazoline derivatives,processes for their preparation and pharmaceutical compositions comprising them |
US5714493A (en) | 1991-05-10 | 1998-02-03 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase |
US5316906A (en) | 1991-08-23 | 1994-05-31 | Molecular Probes, Inc. | Enzymatic analysis using substrates that yield fluorescent precipitates |
US5204354A (en) | 1992-02-14 | 1993-04-20 | Merck & Co., Inc. | Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders |
GB9205907D0 (en) | 1992-03-18 | 1992-04-29 | Cancer Res Inst Royal | Anti-cancer compounds |
US5430148A (en) | 1992-03-31 | 1995-07-04 | Agouron Pharmaceuticals, Inc. | Antiproliferative quinazolines |
GB9220571D0 (en) | 1992-09-30 | 1992-11-11 | Ici Plc | Quinazoline derivatives |
US5817662A (en) | 1992-11-09 | 1998-10-06 | Cell Therapeutics, Inc. | Substituted amino alkyl compounds |
US5780476A (en) | 1992-11-16 | 1998-07-14 | Cell Therapeutics, Inc. | Hydroxyl-containing xanthine compounds |
AU6087894A (en) | 1993-01-14 | 1994-08-15 | Cell Therapeutics, Inc. | Acetal or ketal substituted therapeutic compounds |
WO1994016704A1 (en) | 1993-01-19 | 1994-08-04 | Cell Therapeutics, Inc. | Oxime-substituted therapeutic compounds |
US5574057A (en) | 1993-02-03 | 1996-11-12 | University Of Utah Research Foundation | Naamidine A extracted from sea sponges and methods for its use as an anti-tumor agent |
US5401745A (en) | 1993-03-19 | 1995-03-28 | Merck & Co., Inc. | Quinazolinones substituted with phenoxyphenylacetic acid derivatives |
US5837703A (en) | 1993-03-31 | 1998-11-17 | Cell Therapeutics, Inc. | Amino-alcohol substituted cyclic compounds |
CA2113229C (en) | 1994-01-11 | 1999-04-20 | Mark Pines | Anti-fibrotic quinazolinone-containing compositions and methods for the use thereof |
AU1831395A (en) | 1994-01-14 | 1995-08-01 | Cell Therapeutics, Inc. | Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf |
WO1995022546A1 (en) | 1994-02-18 | 1995-08-24 | Cell Therapeutics, Inc. | Intracellular signalling mediators |
WO1995024190A2 (en) | 1994-03-07 | 1995-09-14 | Sugen, Inc. | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
US5807861A (en) | 1994-03-24 | 1998-09-15 | Cell Therapeutics, Inc. | Amine substituted xanthinyl compounds |
US5801182A (en) | 1994-03-24 | 1998-09-01 | Cell Therapeutics, Inc. | Amine substituted compounds |
US5756502A (en) | 1994-08-08 | 1998-05-26 | Warner-Lambert Company | Quinazolinone derivatives as cholyecystokinin (CCK) ligands |
US5891879A (en) | 1994-08-31 | 1999-04-06 | Hadasit Medical Research Services & Development Co., Inc. | Quinazolinone-containing pharmaceutical compositions and methods for the use thereof |
IL110831A (en) | 1994-08-31 | 1998-12-27 | Hadasit Med Res Service | Pharmaceutical compositions containing quinazolinone derivatives for preventing restenosis |
US5753664A (en) | 1995-03-16 | 1998-05-19 | Takeda Chemical Industries, Ltd. | Heterocyclic compounds, their production and use |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
CN1090621C (en) | 1995-08-30 | 2002-09-11 | 株式会社大冢制药厂 | Process for producing quinazoline-4-one derivatives |
US5783577A (en) | 1995-09-15 | 1998-07-21 | Trega Biosciences, Inc. | Synthesis of quinazolinone libraries and derivatives thereof |
AU4858596A (en) | 1995-09-15 | 1997-04-01 | Torrey Pines Institute For Molecular Studies | Synthesis of quinazolinone libraries |
DE19546918A1 (en) | 1995-12-15 | 1997-06-19 | Bayer Ag | Bicyclic heterocycles |
US5852024A (en) | 1997-02-11 | 1998-12-22 | Hadasit | Treatment and prevention of adhesions |
EP0884310B1 (en) | 1997-06-09 | 2005-09-07 | Pfizer Products Inc. | Quinazolin-4-one ampa antagonists |
US6060479A (en) | 1997-06-09 | 2000-05-09 | Pfizer Inc | Quinazoline-4-one AMPA antagonists |
US5972929A (en) | 1997-08-21 | 1999-10-26 | Shiseido Co., Ltd. | Quinazolinone derivative, hair growth promoter and external composition for skin using the same |
IL125950A0 (en) | 1997-09-05 | 1999-04-11 | Pfizer Prod Inc | Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy |
WO2000007017A2 (en) | 1998-07-27 | 2000-02-10 | President And Fellows Of Harvard College | Method of high-throughput screening |
WO2001016114A2 (en) | 1999-08-27 | 2001-03-08 | Chemocentryx, Inc. | Heterocyclic compounds and methods for modulating cxcr3 function |
ES2234662T3 (en) | 1999-09-16 | 2005-07-01 | Curis, Inc. | HEDGEHOG SIGNALING ROUTE MEDIATORS, COMPOSITIONS AND USES RELATED TO THEMSELVES. |
KR20050049562A (en) | 1999-10-27 | 2005-05-25 | 싸이토키네틱스, 인코포레이티드 | Methods and compositions utilizing quinazolinones |
US6613798B1 (en) | 2000-03-30 | 2003-09-02 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
AU2001249664C1 (en) | 2000-03-30 | 2008-08-14 | Curis, Inc. | Small organic molecule regulators of cell proliferation |
-
2002
- 2002-11-20 US US10/300,967 patent/US6753428B2/en not_active Expired - Fee Related
- 2002-11-20 WO PCT/US2002/037410 patent/WO2003043995A1/en not_active Application Discontinuation
- 2002-11-20 AU AU2002346471A patent/AU2002346471A1/en not_active Abandoned
-
2004
- 2004-02-06 US US10/773,602 patent/US20040192913A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6794379B2 (en) * | 2001-06-06 | 2004-09-21 | Tularik Inc. | CXCR3 antagonists |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080182864A1 (en) * | 1999-10-27 | 2008-07-31 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
US20070254902A1 (en) * | 1999-10-27 | 2007-11-01 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
US7105668B1 (en) | 1999-10-27 | 2006-09-12 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
US20040254203A1 (en) * | 1999-10-27 | 2004-12-16 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
US8008311B2 (en) | 1999-10-27 | 2011-08-30 | Cytokinetics, Inc. | Methods and compostions utilizing quinazolinones |
US7763628B2 (en) | 1999-10-27 | 2010-07-27 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
US20100063073A1 (en) * | 1999-10-27 | 2010-03-11 | Cytokinetics, Inc. | Methods and Compositions Utilizing Quinazolinones |
US8470838B2 (en) | 1999-10-27 | 2013-06-25 | Cytokinetics, Incorporated | Methods and compositions utilizing quinazolinones |
US7671200B2 (en) | 1999-10-27 | 2010-03-02 | Cytokinetics, Inc. | Quinazolinone KSP inhibitors |
US20060041130A1 (en) * | 2002-02-15 | 2006-02-23 | Cytokinetics, Inc. And Smithkline Beecham Corp. | Syntheses of quinazolinones |
US20040067969A1 (en) * | 2002-02-15 | 2004-04-08 | Gustave Bergnes | Syntheses of quinazolinones |
US20040077668A1 (en) * | 2002-05-09 | 2004-04-22 | Cytokinetics, Inc. | Compounds, compositins, and methods |
US20040077662A1 (en) * | 2002-05-09 | 2004-04-22 | Cytokinetics, Inc. | Compounds, methods and compositions |
US20040082567A1 (en) * | 2002-06-14 | 2004-04-29 | Cytokinetics, Inc. | Compounds, compositions, and methods |
US20060019988A1 (en) * | 2002-06-14 | 2006-01-26 | Cytokinetics, Inc. | Compounds, compositions, and methods |
US20060264449A1 (en) * | 2002-09-30 | 2006-11-23 | Gustave Bergnes | Compounds, compositions, and methods |
US20050148593A1 (en) * | 2003-11-07 | 2005-07-07 | Gustave Bergnes | Compounds, compositions, and methods |
US20050234037A1 (en) * | 2003-12-08 | 2005-10-20 | Gustave Bergnes | Compounds, compositions, and methods |
Also Published As
Publication number | Publication date |
---|---|
US6753428B2 (en) | 2004-06-22 |
AU2002346471A1 (en) | 2003-06-10 |
WO2003043995A1 (en) | 2003-05-30 |
US20030166933A1 (en) | 2003-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6753428B2 (en) | Process for the racemization of chiral quinazolinones | |
US7009049B2 (en) | Syntheses of quinazolinones | |
EP0389352B1 (en) | 4-Fluoro-benzene derivatives, process for their preparation and pharmaceutical compositions containing these compounds | |
JP3081172B2 (en) | Nitrogen-containing heterocyclic compounds | |
EP0107398B1 (en) | Ortho substituted dihydroxy-2(1h)quinazolinone-1-alkanoic acids | |
US20050153964A1 (en) | Novel compounds | |
EP1765810B1 (en) | 2,4-diaminoquinazolines for the treatment of spinal muscular atrophy | |
US7034151B2 (en) | Process for preparing pyrrolotriazine kinase inhibitors | |
AU2002351921B2 (en) | Heterocyclic derivatives of glycinamide and their medical use | |
US6849734B2 (en) | Intermediates useful for preparing 4,6-diaminopyrido[5,4-d]pyrimidines | |
KR20010020386A (en) | Phosphodiesterase 4-Inhibiting Diazepinoindolones | |
TWI294426B (en) | Process for the preparation of ccr-2 antagonist | |
FI77456B (en) | PROCEDURE FOR THERAPEUTIC USE OF THERAPEUTIC ANVAENDBARA 3- / 2- / 4- (2-METHOXIPHENYL) -1-PIPERAZINYL / EECL / -2,4- (1H, 3H) -KINAZOLINDIONDERIVAT. | |
EP0365763A1 (en) | Antiproliferative cyclic compounds | |
US6472425B1 (en) | Methods for treating female sexual dysfunctions | |
EP0810214A1 (en) | Process for producing indoline compounds and intermediates for the production of the same | |
WO2019134556A1 (en) | Compound capable of inhibiting phosphodiesterase 4, preparation method, and medical use thereof | |
EP0593285B1 (en) | Intermediates, and processes thereto, for the preparation of 5,6-dihydropyrrolo[2,3-d]pyrimidines | |
IE42956B1 (en) | 4-amino-3-pyrrole carboxamides | |
SK137597A3 (en) | 1-£'omega'-(3,4-dihydro-2-naphthalenyl)alkyl| cyclic amine derivatives, process for producing the same, and medicinal composition containing the same | |
US6642384B1 (en) | Preparation of chiral 1,2,3,4-tetrahydro-6,7-dialkoxy-3-isoquinolinecarboxylic acid and derivatives | |
FI81089B (en) | 4-piperidyl substituted carboxylic acid derivatives and process for the preparation thereof | |
US6140322A (en) | Amidine and isothiourea derivatives as inhibitors of nitric oxide synthase | |
CN117164526A (en) | 2- (piperazine-2-yl) acetonitrile derivative, and preparation method and application thereof | |
CA1224468A (en) | Ortho substituted dihydroxy-2(1h)quinazolinone-1- alkanoic acids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |